Methylprednisolone treatment, immune activation, and intrathecal inflammation in multiple sclerosis.
Sellebjerg
Finn
F
Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark.
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis; D001921:Brain / Q000473:pathology; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007249:Inflammation; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013116:Spinal Cord / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology
D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D001323:Autoantibodies; D005938:Glucocorticoids; D006684:HLA-DR Antigens; D007136:Immunoglobulins; D008775:Methylprednisolone